QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NAMS

QT29NewAmsterdam Pharma Company N.V.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
29.83
-0.32-1.06%
OverviewShort InterestFilings
NAMSQT29NewAmsterdam Pharma Company N.V.·NASDAQ
OverviewShort InterestFilings
29.83-1.06%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.65
Insider Own18.24%
Shs Outstand116.90M
Perf Week-1.42%
Market Cap3.52BForward P/E-EPS next Y-1.39Insider Trans1.24%Shs Float-Perf Month-11.54%
Enterprise Value3.07BPEG2.86EPS next Q-0.48Inst Own-Short Float-Perf Quarter-2.07%
Income-205487385.00P/S156.20EPS this Y-9.40%Inst Trans-Short Ratio-Perf Half Y-12.83%
Sales22.57MP/B5.49EPS next Y22.82%ROA-29.04%Short Interest-Perf YTD-14.97%
Book/sh5.84P/C-EPS next 5Y-ROE-29.80%52W High42.21 -29.33%Perf Year61.33%
Cash/sh5.44P/FCF-EPS past 3/5Y-ROIC-32.35%52W Low17.63 69.20%Perf 3Y-
Dividend Est.-EV/EBITDA-14.43Sales past 3/5Y-39.33% -Gross Margin97.52%Volatility3.68% 3.56%Perf 5Y-
Dividend TTM-EV/Sales135.92EPS Y/Y TTM37.89%Oper. Margin-953.59%ATR (14)1.80Perf 10Y-
Dividend Ex-Date-Quick Ratio9.76Sales Y/Y TTM39.13%Profit Margin-942.76%RSI (14)38.33Recom2.25
Dividend Gr. 3/5Y-Current Ratio9.76EPS Q/Q18.37%SMA20-7.48%Beta1.39Target Price49.00
Payout0.00%Debt/Eq0.00Sales Q/Q0.00%SMA50-9.48%Rel Volume0.96Prev Close30.15
Employees68LT Debt/Eq-EarningsAug 05SMA200-10.37%Avg Volume1.30MPrice29.83
IPO DateFeb 09, 2021Option/ShortYes / YesEPS/Sales Surpr.13.04% 50.00%Net Debt/EBITDA2.15Volume1,249,816Change-1.06%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-19-26ReiteratedGuggenheimBuy$45
Jan-21-26ReiteratedRBC CapitalOutperform$47
Jan-06-26ReiteratedLeerink Partners$45 → $55
Dec-02-25ReiteratedGoldman SachsNeutral$37
Oct-20-25ReiteratedH.C. Wainwright$48 → $52
Aug-25-25InitiatedWells FargoOverweight$45
Mar-03-25ReiteratedUBS$35 → $41
Dec-30-24InitiatedH.CBuy$48
Nov-20-24ReiteratedLeerink Partners$45
Sep-23-24ReiteratedPiper SandlerOverweight$37
Latest News
Jun-11-26
Jun-11-2610:11AM
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price WeaknessYahoo
Jun-10-26
Jun-10-2612:52AM
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue642346
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit642246
Selling, General and Administrative Excl. Other9510670
Research and Development144142151
Other Operating Expense-201
Operating Income-173-226-176
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)211765
Net Income Before Taxes-166-204-242
Income Taxes
000
Consolidated Net Income-166-204-242
Net Income From Continuing Operations-166-204-242
Net Income-166-204-242
EPS (Recurring)-1.65-1.75-2.56
EPS (Basic, Before Extraordinaries)-1.65-1.75-2.56
EPS (Diluted)-1.65-1.75-2.56
EBITDA-192-242-241
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio52.67173.87—
Gross Margin100.0095.65100.00
Operating Margin-270.31-982.61-382.61
Net Margin-259.38-886.96-526.09
Shares Outstanding11311494
Market Capitalization3,3713,999—
Operating Lease Expense
———
Insider Trading Volume
$33.53$31.29$29.05$26.81$24.57● Close Price0.00M6.51M13.02M19.52M26.03MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kooij Louise FrederikaChief Accounting OfficerMay 26 '26Option Exercise10.07130,0001,309,00089,353May 27 12:00 AM
Kooij Louise FrederikaChief Accounting OfficerMay 26 '26Sale35.6965,0002,319,85024,353May 27 12:00 AM
LANGE LOUIS GDirectorMar 11 '26Sale30.4244,6191,357,23010,360Mar 12 12:00 AM
LANGE LOUIS GDirectorMar 09 '26Option Exercise11.5089,2381,026,23854,979Mar 10 12:00 AM
LANGE LOUIS GDirectorMar 06 '26Sale29.4128,186828,9500Mar 10 12:00 AM
Kastelein Johannes Jacob PieterChief Scientific OfficerMar 09 '26Option Exercise0.00202,8180520,229Mar 09 12:00 AM
Kastelein Johannes Jacob PieterChief Scientific OfficerMar 09 '26Sale30.29101,4093,071,67969,302Mar 09 12:00 AM
Kastelein Johannes Jacob PieterChief Scientific OfficerMar 06 '26Option Exercise0.00188,2480621,638Mar 09 12:00 AM
Kastelein Johannes Jacob PieterChief Scientific OfficerMar 06 '26Sale30.3294,1242,853,84069,302Mar 09 12:00 AM
Kastelein Johannes Jacob PieterChief Scientific OfficerMar 05 '26Option Exercise0.00208,9340715,762Mar 09 12:00 AM
Kastelein Johannes Jacob PieterChief Scientific OfficerMar 05 '26Sale30.30104,4673,165,35069,302Mar 09 12:00 AM
Davidson Michael H.Chief Executive OfficerMar 02 '26Option Exercise0.00887,4140617,851Mar 02 12:00 AM
Davidson Michael H.Chief Executive OfficerMar 02 '26Sale33.25443,70714,753,258174,144Mar 02 12:00 AM
Davidson Michael H.Chief Executive OfficerFeb 26 '26Option Exercise0.00366,6640682,974Feb 26 12:00 AM
Davidson Michael H.Chief Executive OfficerFeb 26 '26Sale33.71183,3326,179,974174,144Feb 26 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR